- Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods StudySandesh Dev
Cardiology Section, Phoenix VA Health Care System, Phoenix, AZ
J Am Heart Assoc 5:e002493. 2016..Mineralocorticoid receptor antagonists (MRAs) are the most underutilized pharmacotherapy for heart failure. Minimal data are available on the barriers to MRA adoption from the perspective of prescribing clinicians...
- Prevalence, correlates, and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement (from the National Cardiovascular Data Registry [NCDR])Sandesh Dev
Phoenix Veterans Affairs Health Care System, Phoenix, Arizona Electronic address
Am J Cardiol 113:314-20. 2014..The observed hospital variation suggests a role for augmentation of clinical guidelines regarding the use of antiarrhythmic drugs for patients undergoing implantation of an ICD...
- Reduction in body weight but worsening renal function with late ultrafiltration for treatment of acute decompensated heart failureSandesh Dev
Duke University Medical Center, Durham, NC, USA
Cardiology 123:145-53. 2012..The safety, effectiveness and indications for ultrafiltration (UF) are not well established. We hypothesized that UF would not worsen renal function in patients with heart failure (HF) who were not responding to medical therapy...
- Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care settingSandesh Dev
Phoenix Veterans Administration Health Care System, AZ, USA
Am Heart J 164:313-319.e5. 2012....
- Link between decisions regarding resuscitation and preferences for quality over length of life with heart failureSandesh Dev
Phoenix VA Health Care System, 650 E Indian School Road, Phoenix, AZ 85012, USA
Eur J Heart Fail 14:45-53. 2012..Therefore, the aim of this study was to determine the association of heart failure patients' resuscitation preferences with survival preferences and mortality in the ESCAPE trial...